# Registry for Stage 2 Type 1 Diabetes

> **NCT06481904** · — · RECRUITING · sponsor: **Sanofi** · enrollment: 200 (estimated)

## Conditions studied

- Type 1 Diabetes

## Interventions

- **DRUG:** TZIELD (teplizumab-mzwv)

## Key facts

- **NCT ID:** NCT06481904
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-27
- **Primary completion:** 2037-01-15
- **Final completion:** 2037-01-15
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06481904

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06481904, "Registry for Stage 2 Type 1 Diabetes". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06481904. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*